New blood test identifies brain tumours more accurately

Researchers at the University of Strathclyde have developed a new blood test for brain tumours that can characterise the biochemical profile of a sample without extensive sample preparation, and accurately detect cancer with an average 87% accuracy. It uses attenuated total reflection- Fourier transform infrared (ATR-FTIR) spectroscopy, in combination with artificial intelligence, to rapidly diagnose the condition in triage conditions. Analysis of serum differentiated cancer and control patients at a sensitivity and specificity of 93.2% and 92.8% respectively.
Dr Paul Brennan, senior clinical lecturer and consultant neurosurgeon at the University of Edinburgh, said: “Diagnosing brain tumours is difficult, leading to delays and frustration for lots of patients. With this new test, we have shown that we can help doctors quickly identify which patients with these non-specific symptoms should be prioritised for urgent brain imaging. This means a more rapid diagnosis for people with a brain tumour, and quicker access to treatment.”
Research lead Dr Matthew Baker, CSO at ClinSpec Diagnostics who are developing the technology, said: “This is the first publication of data from our clinical feasibility study and it is the first demonstration that our blood test works in the clinic. Earlier detection of brain tumours in the diagnostic pathway brings the potential to significantly improve patient quality of life and survival, whilst also providing savings to the health services.”